Compare Synopsys, Inc. (SNPS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs GeneDx Holdings Corp — how do they compare? Synopsys, Inc. trades at $414.11 (market cap $78.68B), while GeneDx Holdings Corp trades at $81.89 (market cap $2.44B). The key difference: Synopsys, Inc. is far larger — about 32.2× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| SNPS | WGS | |
|---|---|---|
Market Cap | $78.68B | $2.44B |
Sector | Technology | Technology |
52-Week High | $625.80 | $167.51 |
52-Week Low | $372.33 | $34.51 |
Enterprise Value | $87.04B | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $411.68, down 1.04% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish overall signal despite recent volatility, with strong analyst support (82.76% buy ratings) and a consensus price target of $551.00. Recent earnings beats and strategic moves like the Ansys acquisition highlight robust growth prospects in the semiconductor design software space, though high valuation multiples and significant cash flow volatility warrant caution.
The outlook for SNPS remains positive driven by AI-driven demand and recurring revenue streams, but investors face risks from elevated valuations, integration challenges from acquisitions, and semiconductor cycle sensitivity. The stock's current price near key support levels offers a potential entry point for long-term growth investors, contingent on sustained execution and market conditions.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
